ADARx Posts Q3 Loss, $901M Cash Into 2030, New Onvuzosiran Phase 2a Data
ADRX sits 19% above its 52-week low of $12.5.
Summary
ADARx reported a $28.1 million third-quarter net loss and $901.0 million in cash and investments it says funds operations into 2030, alongside incremental updates on its three clinical siRNA programs.
Key Events · Earnings and Guidance · ADRX
-
Q3 Net Loss Widens to $28.1M
Net loss was $28.1 million for the quarter ended September 30, 2026, versus $17.9 million a year earlier, as R&D rose to $26.7 million from $19.4 million and G&A to $7.7 million from $5.1 million.
-
Cash Runway Extended Into 2030
Cash, cash equivalents and short-term investments totaled $901.0 million at September 30, 2026, excluding about $62.3 million of net proceeds received October 1 from the underwriters' full option exercise.
-
Onvuzosiran Phase 2a Interim Data
All three Phase 2a patients were attack-free for three months after the initial dose, and one patient remained attack-free for 21 consecutive months on Q6M dosing; Phase 3 STOP-HAE topline is guided to year-end 2027.
-
ADX-626 Drops Higher Phase 1 Doses
ADARx will not evaluate doses above the 400 mg cohort in the ongoing Phase 1 FXI trial and intends to test higher doses in the planned Phase 2a/b trial in secondary stroke prevention, targeted for 2027.
Analysis · ADRX · Life Sciences
The balance sheet is the headline in this first quarterly report since the September IPO: $901.0 million of cash and short-term investments at September 30, plus roughly $62.3 million of October option proceeds, funds operations into 2030. That removes any near-term financing need for a company burning about $34.4 million a quarter in operating expenses. Clinical updates are incremental rather than transformative — three Phase 2 agazisiran trials continue, onvuzosiran holds Fast Track for HAE with Phase 3 topline guided to year-end 2027, and ADX-626 will skip higher Phase 1 doses in favor of testing them in Phase 2. The stock's next real test is the agazisiran IgAN nine-month UPCR data expected mid-2027.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADRX was trading at $14.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $12.50 to $23.21. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.